Orange Book product · Brand (NDA)
KENGREAL
CANGRELOR
At a glance
Jun 22, 2015
Approved
Brand (NDA)
Application
AP
TE code
7
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 22, 2015
11 yr 2 mo ago
Today
Patent 9925265 expires
Listed method-of-use patent (U-2260) expiration.
May 13, 2029
in 2 yr 11 mo
Patent 9427448 expires
Listed method-of-use patent (U-1926) expiration.
Nov 10, 2030
in 4 yr 6 mo
Patent 8680052 expires
Listed method-of-use patent (U-2979) expiration.
Mar 09, 2033
in 6 yr 10 mo
Patent 10039780 expires
Listed method-of-use patent (U-2260) expiration.
Jul 10, 2035
in 9 yr 2 mo
Patent 9295687 expires
Listed drug product patent expiration.
Jul 10, 2035
in 9 yr 2 mo
Patent 9439921 expires
Listed drug product patent expiration.
Jul 10, 2035
in 9 yr 2 mo
Patent 9700575 expires
Listed drug product patent expiration.
Jul 10, 2035
in 9 yr 2 mo
Pharmaceutical detail
Active ingredient
CANGRELOR
Strength
50MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
AP
Application
NDA 204958
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9925265 | May 13, 2029 | in 2 yr 11 mo | U-2260 |
| 9427448 | Nov 10, 2030 | in 4 yr 6 mo | U-1926 |
| 8680052 | Mar 09, 2033 | in 6 yr 10 mo | U-2979 |
| 10039780 | Jul 10, 2035 | in 9 yr 2 mo | U-2260 |
| 9295687 | Jul 10, 2035 | in 9 yr 2 mo | Product |
| 9439921 | Jul 10, 2035 | in 9 yr 2 mo | Product |
| 9700575 | Jul 10, 2035 | in 9 yr 2 mo | Product |
